AGP Picks
View all

Bronchitis treatment market seen reaching $8.46 billion by 2030

Nov. 6, 2026
Bronchitis treatment market seen reaching $8.46 billion by 2030
By AI, Created 14:45 UTC, Nov 06, 2026, AGP -

The bronchitis treatment market is projected to grow from $6.37 billion in 2026 to $8.46 billion by 2030, driven by rising respiratory disease prevalence, aging populations and wider use of digital inhalers and telehealth. North America held the largest share in 2025, according to The Business Research Company.

Why it matters: - Bronchitis treatment demand is rising as respiratory disease rates climb worldwide. - The market’s growth matters for drug makers, healthcare providers and digital respiratory-care companies tracking where treatment demand is shifting. - The report points to more use of inhalation therapies, home-based care and remote monitoring, which could change how bronchitis is managed.

What happened: - The Business Research Company released a 2026 bronchitis treatment market report covering market size, trends and forecasts through 2035. - The market grew from $5.92 billion in 2025 to $6.37 billion in 2026. - The report projects the market will reach $8.46 billion by 2030. - North America held the largest market share in 2025.

The details: - The report ties recent growth to rising respiratory infections, smoking habits, urban air pollution, broad use of bronchodilators and antibiotics, and established hospital respiratory-care systems. - The forecast period is supported by preventive respiratory care, wider adoption of digital inhalers, expanding telehealth for respiratory patients, an aging population and greater awareness of chronic respiratory disease management. - Key trends highlighted in the report include combination drug therapies, inhalation-based medication delivery, symptom management, home-based respiratory care and improved monitoring for chronic bronchitis patients. - Bronchitis treatment targets inflammation of the bronchial tubes and often focuses on easing mucus buildup, opening airways and treating infection. - Common treatment approaches include bronchodilators, steroids and antibiotics. - The report’s regional coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis, and updated graphics and tables. - A free sample is available here. - The full report is available here.

Between the lines: - Rising asthma and COPD numbers reinforce the report’s central premise that more people will need respiratory treatment over time. - Public Health Wales and National Health Service Wales reported that 237,400 people were registered with asthma and 75,600 with COPD in 2023/24. - Those figures are projected to rise to 256,400 asthma cases and 84,800 COPD cases by 2033/34. - The forecast suggests bronchitis treatment is moving from a largely clinic-based category toward more digital and home-supported care.

What’s next: - The report expects the market to keep growing at a 7.4% CAGR through 2030. - Wider use of telehealth, digital inhalers and remote monitoring may shape the next phase of bronchitis care. - Ongoing respiratory disease prevalence will likely remain a key driver of demand.

The bottom line: - Bronchitis treatment is turning into a steady-growth respiratory market, with aging populations, chronic disease rates and digital care tools pushing demand higher.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.